Can-Fite BioPharma (CANF) announced an update related to the intellectual property, IP, status of its lead drug candidate Namodenoson, currently being developed for the treatment of Metabolic Dysfunction-associated Steatohepatitis, MASH, advanced liver cancer and pancreatic cancer. In all clinical studies that have been conducted, Namodenoson had a very favorable safety profile when administered orally.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma Secures Lucrative Deal with Vetbiolix
- Can-Fite BioPharma reports results from osteoarthritis clinical study in dogs
- Can-Fite’s Namodenoson Gains FDA Orphan Status
- Can-Fite BioPharma announces FDA granted ODD for Namodenoson
- Can-Fite BioPharma treatment of pancreatic cancer granted FDA orphan status